P atients with cirrhosis have increased morbidity from hepatitis A virus (HAV) and hepatitis B virus (HBV) infections, and vaccination against these infections is an important standard of care.
Patients and Methods
We performed a single-center, prospective, nonrandomized controlled trial, comparing SD vs HDA HAV and HBV regimens in consecutive patients with cirrhosis.
The SD HAV schedule comprised intramuscular Twinrix (GlaxoSmithKline, Australia) 720 mg at 0, 1, and 6 months. For 23% of patients the SD HAV schedule was intramuscular Havrix (GlaxoSmithKline) 1440 mg at 0 and 6 months. For patients failing to seroconvert, a single 1440-mg Havrix booster was given. The HDA HAV schedule was Havrix 1440 mg at 0, 1, and 2 months, with a single 720-mg booster for patients failing to seroconvert.
The SD HBV schedule was intramuscular Twinrix or Engerix-B (GlaxoSmithKline) 20 mg at 0, 1, and 6 months with a 40-mg booster of Engerix-B if nonimmune. The HDA HBV schedule was Twinrix or Engerix-B 40 mg at 0, 1, and 2 months, with the schedule repeated as a booster if nonimmune. The combined vaccine Twinrix was used for initial vaccination in 48% of patients.
The HDA regimens were designed after a review of the literature and to provide approximately double the SD in one third of the time. The SD (HAV and HBV) cohort study occurred during the time period of 2009 to 2011. The HDA cohort study occurred during a separate time period during 2012 to 2014.
For multivariate models those variables that were significant at P < .20 were considered for inclusion in the model.
Results
In the HAV arm, 73 and 35 patients received SD and HDA schedules, respectively. In the HBV vaccination arm, 97 and 51 patients received the SD and HDA regimens, respectively. Groups were well matched for important clinical characteristics. The percentage of patients with decompensated (Child-Pugh B/C) disease in the HAV and HBV study arms was 38% and 43%, respectively. Eighteen patients did not adhere to boosting protocols and were excluded from relevant per-protocol analyses.
In the HAV arm, initial response rates were 79.5% (58 of 73) in the SD arm and 94.3% (33 of 35) in the HDA arm (P ¼ .065). Boosting regimens were successful in 66.7% (8 of 12) in the SD arm and in 100% (1 of 1) in the HDA arm. Per-protocol immune response rates for the SD HAV vaccination arm was 94.3% (66 of 70), and 100% (34 of 34) in the HDA arm (P ¼ .16).
In the HBV arm, the initial response rates were 51.5% (50 of 97) in the SD arm and 45.1% (23 of 51) in the HDA arm (P ¼ .49). Boosting regimens were successful in 28.6% (12 of 42) in the SD group and in 52.6% (10 of 19) in the HDA arm (P ¼ .07). Perprotocol immune response rates were 67.4% (62 of 92) in the SD arm and 78.6% (33 of 42) in the HDA arm (P ¼ .19).
Only 1 factor across both HAV and HBV studies-low albumin in the HBV SD arm-was associated significantly with immune nonresponse on multivariate analysis (Table 1 and Supplementary Table 1) .
There were no vaccination-related serious adverse events seen in any patients.
15% improved immune response, rapid immune response, and minimal increased cost.
Results do not support the routine use of the initial HDA HBV vaccination regimen in cirrhotic patients, but do suggest a potential benefit from HDA boosting of initial nonresponders. The HDA boosting regimen was associated with a clinically significant 23% improved response rate.
Neither HAV nor HBV immune nonresponse was associated with model for end-stage liver disease or Child-Pugh score or older age, as suggested by some investigators. [3] [4] [5] [6] [7] The association of low albumin (a possible surrogate for advanced liver disease) with nonresponse to the SD HBV vaccine, suggests that the HDA boosting regimen may have the greatest utility in these patients.
The nonrandomized study design and lack of statistical power were weaknesses of our study, which limited our ability to draw firm conclusions. A post hoc power analysis suggested that 76 patients (HAV) and 120 patients (HBV) per group were required for the trends seen in initial HDA HAV and secondary HDA HBV immune responses to achieve statistical significance. Nevertheless, it should be noted that there are no randomized studies in this field and our study represents one of the largest vaccination studies in cirrhotic patients to date. A further strength was the selection of a cirrhotic population with a range of disease severity and etiology, enabling improved external generalizability of findings to cirrhotic patients typically seen in hepatology services.
In conclusion, we believe the study findings provide the rationale for future randomized, adequately powered studies investigating benefits of an initial HAV HDA regimen and a secondary HBV HDA boosting regimen in cirrhotic patients.
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